Pharmaceutical Executive podcast

Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.

0:00
2:53
15 Sekunden vorwärts
15 Sekunden vorwärts
FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’ collaboration with Astellas, and Incubate’s John Stanford on which therapeutic areas MFN deals might hit hardest.

Weitere Episoden von „Pharmaceutical Executive“